Alluvi, formerly BI 4744, offers a notable breakthrough in obesity therapy. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates remarkable efficacy in research https://alluvi-peptides215107.itbloghub.com/profile